International R&amp;D Networks

Zu, Lei; Dong, Baomin; Zhao, Xin; Zhang, Jin

doi:10.1111/j.1467-9396.2011.00950.x

Cited by 17 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the theoretical R&D literature, the most common stable R&D structure is a complete network (Goyal and Moraga-Gonzalez 2001; Goyal and Joshi 2003; Song and Vannetelbosch 2007; Deroian 2008; Westbrock 2010; Zu et al. 2011; Konig et al. 2012; Zirulia 2012).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Economic returns in forming stable R&D networks

Alghamdi

2016

SpringerPlus

View full text Add to dashboard Cite

The aim of this paper is to study the individual and social benefits behind constructing stable R&D networks. We find that the equilibrium outcomes of a stable network are related to the number of competitors. As they increase, the individual outcomes and the total welfare decrease. This implies that in the individual and social perspectives, small stable networks are more desirable than the large ones. Furthermore, when comparing the stability of the components of a network with a complete network, we conclude two main observations. The first observation shows that the stability of the components of a network does not necessarily guarantee a stable overall network. The second observation suggests that firms prefer to be part of a complete network rather than part of a stable component of a network. This preference depends on the profit of firms where it is maximized when firms are belong to the complete network.

show abstract

Section: Introductionmentioning

confidence: 99%

“…2011). Song and Vannetelbosch (2007) studied the case when there are three firms belonging to different countries and producing homogeneous goods.…”

Section: Introductionmentioning

confidence: 99%

Economic returns in forming stable R&D networks

Alghamdi

2016

SpringerPlus

View full text Add to dashboard Cite

show abstract

“…However, having in mind that research collaborations and networks are nowadays considered as essential elements to generate innovations in the knowledge based economy in general [17]–[19], and also in the pharmaceutical sector, the analysis of such cross-country R&D collaborations constitutes an important additional element when investigating the dominance of the US in global pharmaceutical innovation. This is related to the increasing complexity of finding new drugs, on the one hand, and, on the other hand, to the dramatically improving accessibility and mobility of research resources across geographical space [20].…”

Section: Introductionmentioning

confidence: 99%

Is the United States Still Dominant in the Global Pharmaceutical Innovation Network?

Scherngell

Man

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

The dramatic growth of research and development activities in the pharmaceutical sector in emerging economies raises the question of whether the United States still keeps its dominant role in the global pharmaceutical innovation landscape. This paper focuses on investigating the role of the United States in global pharmaceutical innovation, and differs from previous studies by shifting attention to a network analytic perspective to track the global distribution of pharmaceutical inventions. Our sample is composed of key patents covering all new drugs approved by the Food and Drug Administration between 1996 and 2010. The results show that the United States still dominates in the global pharmaceutical innovation network, especially when it comes to essential core inventions. However, the United States shows a slightly decreasing prominence in the networks of either total new drugs or New Molecular Entity (NME) drugs in the time period 2006–2010 as compared to previous time periods, revealed by subtle traces of network centralities.

show abstract

“…What is important in these ventures is a pairwise stable R&D, where both firms have the same strength in this activity. This way, opportunistic behaviour can be diminished (Zu et al, 2011). Zhang et al (2010) added that inter-firm cooperation and competition coexist in strategic alliances and both factors increase knowledge acquisition, although from different motivational bases.…”

Section: Best Practices For International Randd Partnershipsmentioning

confidence: 99%

“…When firms adopt an equity joint venture structure, the opportunistic behaviour can be mitigated due to the shared ownership (Oxley and Sampson, 2004). Zu et al (2011) suggested another type of partnership by a research joint venture (RJV). In this partnership, the firms cooperate in R&D but compete in product markets.…”

Section: Best Practices For International Randd Partnershipsmentioning

confidence: 99%

International Partnership as a Tool to R&D Achievements

Zarpelon

Gavronski

2015

JOSCM

View full text Add to dashboard Cite

ABSTRACT:Global competition emerges with a greater need for faster innovations. R&D plays an essential role in the elaboration of new products and processes in an even shorter period. As the access to resources and knowledge inside the own country borders are restricted, firms start to go abroad looking for other options of R&D. This way, international R&D partnerships arise as an important theme for theory and practice. Through a systematic literature review of 31 papers published in management journals from 2002 to 2014, this study brings two streams of the literature. First, a description of the main concepts in international R&D partnerships. Second, the best practices for the theme proposed and the gaps in the area's knowledge. This paper contributes to both practitioners and literature by providing a research agenda with seven themes for future research, regarding in-depth studies, secondary data analysis, measure proposal and managerial implications.

show abstract

International R&D Networks

Cited by 17 publications

References 16 publications

Economic returns in forming stable R&D networks

Economic returns in forming stable R&D networks

Is the United States Still Dominant in the Global Pharmaceutical Innovation Network?

International Partnership as a Tool to R&D Achievements

Contact Info

Product

Resources

About